GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AtriCure Inc (NAS:ATRC) » Definitions » Net Income

AtriCure (AtriCure) Net Income : $-30.4 Mil (TTM As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is AtriCure Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. AtriCure's Net Income for the three months ended in Dec. 2023 was $-9.8 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-30.4 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. AtriCure's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.21.


AtriCure Net Income Historical Data

The historical data trend for AtriCure's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AtriCure Net Income Chart

AtriCure Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -35.19 -48.16 50.20 -46.47 -30.44

AtriCure Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.17 -6.48 -5.12 -9.06 -9.79

AtriCure Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

AtriCure's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-29.847+-0.591+0+3.5527136788005E-15
=-30.4

AtriCure's Net Income for the quarter that ended in Dec. 2023 is calculated as

Net Income(Q: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-9.416+-0.373+0+0
=-9.8

Net Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-30.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AtriCure  (NAS:ATRC) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

AtriCure's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


AtriCure Net Income Related Terms

Thank you for viewing the detailed overview of AtriCure's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


AtriCure (AtriCure) Business Description

Traded in Other Exchanges
N/A
Address
7555 Innovation Way, Mason, OH, USA, 45040
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
Executives
Karl S. Dahlquist officer: Chief Legal Officer 7555 INNOVATION WAY, MASON OH 45040
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
Maggie Yuen director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Vinayak Doraiswamy officer: Chief Scientific Officer 7555 INNOVATION WAY, MASON OH 45040
Deborah Lee Yount officer: Chief Human Resources Officer 7555 INNOVATION WAY, MASON OH 45040
Tonya Austin officer: Chief Human Resources Officer 7555 INNOVATION WAY, MASON OH 45040
Angela L Wirick officer: Chief Financial Officer 7555 INNOVATION WAY, MASON OH 45040
Mark A Collar director 382 BISHOPBRIDGE DR, CINCINNATI OH 45255
Regina E Groves director 5751 COPLEY DRIVE, SAN DIEGO CA 92111
Douglas J Seith officer: SVP of Sales and Marketing 7555 INNOVATION WAY, MASON OH 45040
Salvatore Privitera officer: VP; Product Development 7555 INNOVATION WAY, MASON OH 45040
Justin J Noznesky officer: SVP, Mktg & Business Develop 7555 INNOVATION WAY, MASON OH 45040
Deborah H Telman director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Scott William Drake director 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Sven Wehrwein director